3rd generation glp 1 agonist 🚨 HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average Eli Lilly's retatrutide shows promising

The involvement of medicinal chemists will also help delineate the impacts of different structural changes, such as different terminal linkages with GSH ( C -terminal, S -terminal, and N -terminal), on binding selectivity and efficiency, and establish structure-activity relationships (SAR) for the development of glutathione transporter-based brain targeting ligands

Moving to the ability of metformin to reduce the metastatic potential, it was demonstrated that the drug not only reduced the migration of MTC cancer cells (Klubo-Gwiezdzinska et al., 2012), but also modified the expression of several markers of the epithelial-tomesenchimal-transition (EMT) (Han et al., 2015)

It was originally FDA-approved in the 1990s to diagnose and treat growth hormone deficiency in children

doi: 10.1210/jc.2005-1536 81 CorpasEHarmanSMPieyroMARobersonRBlackmanMR

Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE

GHK-Cu Safety Guideline Yes, GHK-Cu is generally safe when used in a moderate doses & is reviewed under professional supervision